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size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to
reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.
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followed by oral spironolactone for 3 months or matching placebo. The primary endpoint was MI size by cardiovascular
magnetic resonance at 3 months.
Results Sixty-seven patients completed the study. There was no significant difference in the final MI size at 3 months
between the 2 groups (placebo: 17 ± 11%, MRA: 16 ± 10%, P = .574). There was also no difference in acute MI size (26 ±
16% versus 23 ± 14%, P = .425) or myocardial salvage (26 ± 12% versus 24 ± 8%, P = .456). At follow-up, there was a trend
towards an improvement in LVEF (placebo: 49 ± 8%, MRA: 54 ± 11%, P = .053), and the MRA group had significantly greater
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hMortality in patients with acute ST-segment elevation
myocardial infarction (STEMI) has declined over the past 4
decades1 but morbidity due to post-myocardial infarction
(MI) heart failure, risks for arrhythmias and repeat ischemic
events remains significant.2 The process of reperfusion itself
can paradoxically induce further myocardial injury and
cardiomyocyte death as a consequence of ‘myocardial
reperfusion injury’3 and the latter can contribute up to
50% of the final MI size.4 Despite a wealth of research in this
field, there is currently no effective therapy for reducing
myocardial reperfusion injury.5 This has been partly
attributed to the unfavorable timing and mode of delivery
of the cardioprotective agent; poor selection of patients; and
suboptimal choice of endpoints.5
Pre-clinical data inmurine, rat and rabbit in vivomodels of
MI have demonstrated that administering either intravenous
potassium canrenoate (a compatible metabolite of
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myocardial ischemia and 5 minutes prior to reperfusion,
protected the heart against myocardial reperfusion injury
and reduced MI size by 40–50%.6
Therefore, the MINIMIZE STEMI trial7 was designed to
assess the benefit of mineralocorticoid receptor antago-
nist (MRA) therapy in STEMI patients without heart
failure on reducing MI size and preventing adverse left
ventricular (LV) remodeling. We hypothesized that early
intravenous MRA therapy administered prior to restora-
tion of flow in the infarct-related artery, followed by
3 months oral MRA therapy could reduce MI size and
improve LV remodeling in STEMI patients.
Methods
Study population
The MINIMIZE-STEMI trial (https://clinicaltrials.gov,
NCT01882179) was a prospective, proof-of-concept,
multi-center, double-blinded randomized placebo con-
trolled clinical trial.7 The study was conducted in
accordance with the Declaration of Helsinki and was
approved by the UK National Research Ethics Service. All
patients provided written informed consent. Consecutive
STEMI patients were screened from 4 centers in the
United Kingdom between December 2013 and January
2016. The study design has been previously described.7
In brief, the main inclusion criteria were patients N18
years, with an acute STEMI (as assessed by 12 lead ECG;
ST segment elevation ≥2 mm (0.2 mV) in 2 or more
contiguous precordial leads or ≥1 mm (0.1 mm) in 2 or
more adjacent limb leads), presenting within 12 hours of
symptoms onset. The angiography inclusion criteria were
TIMI 0 in a proximal left anterior descending, circumflex
or right coronary artery territory STEMI and the initial
serum potassium of b5.0 mmol/l. Patients with known
previous MI, heart failure or LVEF ≤40%, in cardiogenic
shock, estimated glomerular filtration rate b30 mL/min
per 1.73 m2, unable to consent, on pre-existing MRA
therapy or with known contraindication to cardiovascu-
lar magnetic resonance (CMR) imaging were excluded.
Study protocol
On immediate arrival at the primary percutaneous
coronary intervention (PPCI) center, eligible patients
were consented to enter the MINIMIZE STEMI trial.
Patients were randomized via a web-based service (www.
SealedEnvelope.com) in a 1:1 manner to either MRA
therapy or matching placebo. Randomization was strat-
ified by recruiting site. The study drug or placebo was
administered by the unblinded research investigator. The
patient, PPCI operator, and research staff collecting the
data were blinded to the treatment allocation.
MRA therapy. Patients randomized to MRA therapy
received an intravenous bolus of 200 mg (10 ml) of
potassium canrenoate8 prior to restoration of flow in theinfarct-related artery, followed by oral spironolactone 25
mg once daily for 2 weeks and then 50 mg once daily (if
serum potassium level allowed) for the remaining 10
weeks. Renal function was assessed at 2 and 4 weeks.
Placebo. Patients randomized to placebo received a 10
ml intravenous bolus of normal saline followed by
placebo tablets for the 3 months.
Patients with an LVEF ≤40% on the initial CMR scan and
evidence of heart failure or who were diabetic were started
on open-label eplerenone according to current practice
guidelines. These patients were included in the intention-to-
treat analysis. A CMR was performed within the first week
following PPCI and was repeated 3 months later. A pre-
specified interim analysis was planned on safety grounds.
The primary endpoint was MI size by CMR at 3 months.
Pre-specified secondary endpoints included acute MI size
by CMR, extent and incidence of microvascular obstruc-
tion (MVO) on CMR, myocardial salvage and indices of LV
remodeling (end-diastolic volume (LVEDV), end-systolic
volume (LVESV) and LVEF.
In addition to the above analysis of pre-specified
outcomes, two post-hoc outcomes were examined:
percentage change in LVEDV and percentage change in
LVESV. These were defined using the equation below:
Volume change %ð Þ
¼ Volume3 monthsVolume1 weekð Þ=volume1 week
x 100
CMR acquisition and analysis
The CMR protocol has been previously described.7 In
brief, all CMR scans were performed on a 1.5 Tesla scanner.
Full short axis LV coverage cine images (for volumes, LVEF
and mass), T2-mapping or T2-weighted imaging (for the
edema-based area-at-risk) and LGE imaging (10 minutes after
0.1 mmol/kg of Gadoterate meglumine for MI size) were
acquired. Matching sequences with the same parameters
were used at follow-up.
All imaging analysis was performed using CVI42 software
(Version 5.1.2[303], Calgary, Canada). The endocardial and
epicardial borders were manually delineated on all the cine,
T2 and LGE short-axis LV images. LVEF, LV volumes and LV
mass were quantified using the summation of discs method.9
A reference regionof interestwasdrawn in the remotenormal
myocardium. The area-at-risk and MI size were quantified
using a signal intensity thresholdof 2 and5 standarddeviations
(SD) above the normal remotemyocardium, respectively.10,11
Areas of hypo-intense core of MVO were included as part of
the MI zone and edema-based area-at-risk.
Myocardial salvage was calculated as area-at-risk by T2
on the first CMR minus the MI size at 3 months and was
expressed as a percentage of the LV.
Sample size calculation
The studywas originally powered for a sample size of 50 in
each group, to give 80% power to detect a difference in
Figure 1
CONSORT diagram for the MINIMIZE STEMI trial. This is a summary of the patient selection, recruitment and follow-up.
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Month Yearmeansof8.0g infarctmassbyCMRassuming that thecommon
standard deviation was 14.0 g.7,12 Accounting for dropouts, a
total sample size of 150 patients was planned. An interim
analysis was performed after 70 patients were recruited.
Statistical analysis
All analysis was performed using Stata version 15.0
(StataCorp, College Station, TX). MI size was compared
between the 2 groups using linear regression with the MI
size as the response variable and the treatment group
included as a binary covariate in the model. The
distribution of both acute and follow-up MI size in
grams showedmarked positive skew, but this distribution
was normalized by expressing MI size as percentage of
the LV and the latter was used for analysis. The extent
of MVO was compared between groups using linear
regression. Due to non-normal distribution of the
outcome, we used non-parametric bias-corrected and
accelerated bootstrapped 95% confidence intervals based
on 2000 replications stratified by treatment group.
Myocardial salvage was expressed as a percentage of LV
and compared using linear regression. Linear regression
was also used to compare the groups on LVEDV, LVESV,
LVEF, and LV mass at 3 months. Analysis of LV mass usedrobust standard errors to allow for heteroscedasticity in
this measure.
Due to observed baseline imbalances between the
groups in participants with clinical data available, we
conducted a post-hoc secondary adjusted analysis of the
primary and secondary endpoints. This analysis adjusted
for age, history of dyslipidemia, infarct-related artery, and
duration of ischemia by including these as predictors in
the linear regression model along with treatment group.Results
Patient recruitment
Nine hundred ninety-five patients were screened from
the 4 centers over the 2-year period. Figure 1 shows the
CONSORT diagram for this study. There were 113
patients randomized at the time of PPCI following brief
informed consent and 70 patients agreed to stay in the
study after the second comprehensive informed consent.
CMR data were available in 67 patients.
Baseline characteristics
Among the 70 patients with clinical data available, there
were some imbalances in the baseline characteristics
Table I. Baseline characteristics of the patients
Placebo (n = 32) MRA (n = 38) P
Age, mean ± SD (years) 60 ± 13 62 ± 10 .47
Male gender (%) 27 (84) 33 (87) 1.0
Smoking status, N (%) .57
Non-smoker 12 (38) 15 (39)
Ex-smoker 11 (34) 9 (24)
Current smoker 9 (28) 14 (37)
Prior diagnoses, N (%)
Hypertension⁎ 11 (34) 13 (35) 1.0
Dyslipidemia 15 (47) 11 (29) .14
Diabetes Mellitus 4 (13) 2 (5) .40
Stroke or TIA 2 (6) 0 (0) .21
PVD 0 (0) 1 (3) 1.00
COPD 2 (6) 9 (24) .06
BMI, mean ± SD (kg/m2)⁎ 28 ± 4 28 ± 4 .47
SBP, mean ± SD (mmHg) 126 ± 22 135 ± 31 .17
DBP, mean ± SD (mmHg) 78 ± 17 88 ± 24 .06
HR, mean ± SD (beats/min) 72 ± 16 75 ± 18 .47
Pre-existing medications, N (%)
Beta-blockers 4 (13) 3 (8) .70
ACEI/ ARB 3 (9) 5 (13) .68
Statins 7 (22) 8 (21) 1.00
Infarct-related artery, N (%) .06
LAD (%) 19 (59) 15 (39)
LCX (%) 3 (9) 1 (3)
RCA (%) 10 (31) 22 (58)
Call to balloon time, median (IQR) (minutes) 144 (115 to 191) 173 (114 to 245) .35
Door to balloon time, median (IQR) (minutes)⁎ 31 (27 to 44) 39 (30 to 53) .29
Radial access (%)⁎ 25 (78) 31 (84) .55
DES use (%) 29 (91) 36 (95) .65
Heparin use (%) 31 (97) 37 (97) .20
Bivalirudin (%) 4 (13) 4 (11) 1.0
Aspirin (%) 30 (94) 36 (95) .63
Clopidogrel (%) 7 (22) 8 (21) .58
Prasugrel (%) 6 (19%) 10 (26%) .32
Ticagrelor (%) 19 (59) 19 (50%) .29
Abbreviations: SD, Standard deviation; TIA, transient ischemic attack; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate;ACEI: angiotensin-converting enzyme inhibitor;ARB: angiotensin receptor blocker; LAD, left anterior descending
artery; LCX, left circumflex artery; RCA, right coronary artery; IQR, inter-quartile range; DES, drug-eluting stent.
⁎ These characteristics were recorded for the following numbers of patients: hypertension, door to balloon time, and radial access N = 69; BMI N = 68. All other characteristics were
recorded for N = 70 patients.
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MRA group were more likely to have higher blood pressure
and higher heart rate on admission, and were more likely to
be smokers (Table I). Those in the MRA group were less
likely to have a history of dyslipidemia (29% vs 47%), but
were more likely to have a family history of coronary artery
disease (53%vs 41%) than those in theplacebogroup (Table I).
Medication use at baseline was broadly similar in the two
groups.The infarct-relatedarterywasmost likely tobe the right
coronary artery in the MRA group but the left anterior
descending artery in the placebo group. Duration of ischemia
and call to door timewere bothmore likely to be longer in the
MRA group than in the placebo group (Table I). These
imbalances motivated the secondary post-hoc analysis, as
described above, which adjusted for the potentially important
prognostic characteristics that appeared to showan imbalance
between the two groups.One patient in the MRA group died during the follow-
up period and 2 patients from the same group had mild
and transient episodes of hyperkalemia.
Primary and secondary endpoints
Three patients in the MRA group and 1 patient in the
placebo group were discharged on open-label MRA
therapy (eplerenone) as per current guidelines.1314Intention-to-treat analysis
There was no significant difference in the primary
endpoint of MI size at 3 months between the 2 groups
(placebo group: mean ± SD 17 ± 11%, MRA group: 16 ±
10%, P = .574, Figure 2b). There was also no difference in
acute MI size (placebo group: 26 ± 16%, MRA group: 23 ±
14%, P = .425, Figure 2a) or myocardial salvage (placebo
Figure 2
Bar charts of acute (a) and chronic (b) MI size and box and whisker plots of percentage change in LVESV (c) and LVEDV (d) in the placebo and
MRA therapy group. There was no significant difference in both (a) acute and (b) chronic MI size as shown in the bar charts. There was significant
great percentage reduction in (c) LVEDV and (d) LVESV in the MRA group as shown in the box and whisker plots.Bar charts: box representing
mean and error bars represent ± 2 × standard error.Box and whisker plot: box representing median and interquartile range and whiskers
representing maximum and minimum.
Table II. Primary analysis and secondary post hoc adjusted analysis of the primary and secondary outcomes
Outcome
Placebo MRA Primary analysis Secondary post-hoc adjusted analysis
N Mean ± SD N Mean ± SD
Difference in
means⁎ 95% CI P
Difference in
means⁎⁎ 95% CI P
Acute CMR
MI size (%LV) 27 26 ± 16 34 23 ± 14 −3.1 −10.7 to 4.6 .425 0.8 −6.4 to 8.0 .819
MVO (g)⁎⁎⁎ 27 5 ± 9 34 4 ± 8 −0.6 −6.0 to 3.0 0.4 −3.6 to 3.3
Follow-up CMR
MI size (%LV) 30 17 ± 11 32 16 ± 10 −1.5 −6.8 to 3.8 .574 0.6 −4.2 to 5.4 .795
EDV (ml) 30 188 ± 52 32 171 ± 46 −17.1 −41.9 to 7.7 .174 0.3 −23.8 to 24.4 .979
ESV (ml) 30 99 ± 40 32 82 ± 37 −16.2 −35.8 to 3.4 .104 −2.4 −21.0 to 16.2 .799
LV mass (g) 30 116 ± 21 32 112 ± 25 −3.7 −15.6 to 8.1 .531 0.4 −12.1 to 13.0 .945
LVEF (%) 30 49 ± 8 32 54 ± 11 4.8 −0.1 to 9.7 .053 1.9 −2.8 to 6.7 .412
Acute + follow-up CMR
Myocardial salvage (%LV) 28 26 ± 12 32 24 ± 8 −1.9 −7.0 to 3.2 .456 1.1 −4.1 to 6.3 .662
Change in LVEDV (%) 27 10 ± 14 31 −3 ± 16 −12.3 −20.3 to −4.4 .003 −9.3 −17.9 to −0.6 .036
Change in LVESV (%) 27 6 ± 20 31 −12 ± 24 −18.2 −30.1 to −6.3 .003 −16.9 −29.9 to −3.8 .012
Abbreviations: SD, Standard deviation; CI, confidence interval;MI, myocardial infarction;MVO, microvascular obstruction; LV, left ventricle; LVEDV, LV end-diastolic volume; LVESV,
LV end-systolic volume; LVEF, LV ejection fraction.
⁎Difference estimated from a simple linear regression model with a binary indicator variable for treatment group.
⁎⁎Difference estimated from a linear regression model with a binary indicator variable for treatment group, and adjusting for age, history of dyslipidemia (high cholesterol), infarct-
related artery, and duration of ischemia.
⁎⁎⁎Due to non-normal distribution of this outcome, inference was based on 95% CI from bias corrected accelerated bootstrapping with 2000 replications and no P value can be provided.
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the 2 groups.
The other CMR parameters between the 2 groups are
provided in Table II. There was no difference in the
extent of MVO between the 2 groups. However, there
was a significantly greater percentage decrease in LVESV
in the MRA therapy group compared to placebo (mean
difference: −18.2 (95%CI −30.1 to −6.3)%, P = .003) and
also significant evidence for more favorable change in
LVEDV (mean difference: −12.2 (95% CI −20.3 to −4.4)%,
P = .003) (Table II and Figure 2c and d). There was no
difference in the baseline LVEF between the 2 groups
(placebo group: 46 ± 9%, MRA group: 48 ± 9%, P = .283).There was a trend towards an improvement in LVEF at
follow-up but this did not reach statistical significance
(placebo group: 49 ± 8%, MRA group: 54 ± 11%, P = .053).Per-protocol analysis
There was no significant difference in the primary
endpoint of MI size at 3 months between the 2 groups
(placebo group: 17 ± 11%, MRA group: 14 ± 9%, P =
.288). There was also no difference in acute MI size
(placebo group: 26 ± 16%, MRA group: 21 ± 12%, P =
.195) or myocardial salvage (placebo group: 26 ± 12%,
MRA group: 23 ± 8%, P = .418) between the 2 groups.
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follow-up when compared to the placebo group (55 ± 10%
versus 49±8%,P= .016) and significantly greater percentage
decrease in LVESV and LVEDV (P b .001 for both).
Adjusted post-hoc analysis
The results of the post-hoc secondary analysis, adjusted
for age, history of dyslipidemia, infarct-related artery, and
duration of ischemia are shown in Table II and they were
very similar to the unadjusted analysis.
There was no evidence of a difference between the
placebo group and MRA group on MI size at 3 months
post-PPCI. After adjustment, the mean follow-up MI size
was 0.6 percentage points higher in the MRA group
compared to placebo (95% CI −4.2 to 5.4; P = .80). There
was also no evidence of a difference between the placebo
group and MRA group for MVO, myocardial salvage,
acute MI size and pre-specified measures of LV remodel-
ing (Table II). However, those randomized to the MRA
group had a significantly greater percentage decrease in
LVEDV and LVESV between the follow-up and acute CMR
(Table II).Discussion
This pilot study showed thatMRA therapy initiated prior to
reperfusion and continued for 3 months did not reduce
reperfusion injury in STEMI patients treated by PPCI, when
compared to placebo. However, those receiving MRA
therapy showed less adverse LV remodeling at follow-up.
In the pre-clinical setting, intravenous potassium
canrenoate (a compatible metabolite of spironolactone)
or eplerenone have been shown to protect the heart
against myocardial reperfusion injury and to reduce MI
size significantly in rats, mice and rabbits.6 However, van
den Berg et al.15 recently showed that eplerenone did not
reduce ischemia–reperfusion injury in an ex-vivo model
of human atrial tissue obtained from 24 patients
undergoing cardiac surgery. Therefore our study was
important, as it was the first study to assess whether MRA
therapy administered prior to reperfusion provided a
benefit against reperfusion injury and led to smaller MI
size in the clinical setting. Furthermore, the patients also
had 3 months of oral MRA therapy to assess whether our
approach led to better post-MI LV remodeling at 3 months
in those not meeting the criteria for MRA therapy.
MRA therapy has already been shown to prevent
adverse LV remodeling following acute MI as summarized
in a previous meta-analysis,16 and the findings from our
study are consistent with this. The role of MRA therapy in
acute MI patients with LVEF ≤40% and with signs and
symptoms of heart failure or diabetes is well estab-
lished.13,1417 However, the impact of MRA therapy on
clinical outcomes in acute MI patients without heart
failure is less well established. The REMINDER trial
investigated the effect of initiating oral eplerenonetherapy 12–24 hours following STEMI admission (in the
absence of heart failure) in 1012 acute STEMI patients.18
There was a reduction in their composite endpoint in
favor of eplerenone but this was mainly driven by lower
brain natriuretic peptide levels. The ALBATROSS trial
investigated the effect of MRA therapy (IV bolus of
potassium canrenoate (200 mg) followed by a daily 25-mg
dose of spironolactone for 6 months) initiated within 72
hours of symptom onset in 1603 patients with either
NSTEMI or STEMI (regardless of heart failure status) on
the 6 month primary combined endpoints.19 They failed to
show the benefit of early MRA use in addition to standard
therapy in that study. However, an exploratory analysis
showed that there was a mortality benefit in the STEMI
subgroup among those randomized to MRA therapy.19 A
recent pooled analysis from the ALBATROSS and REMINDER
trials reported that there were significantly fewer deaths in
the MRA-treated patients when compared to controls after a
median of 6 months follow-up.20 Two large meta-analyses
recently showed that the mortality benefit was mainly in
those patientswith post-MI heart failure21 aswell as in STEMI
patientswithout heart failure.22 Thebeneficial effects ofMRA
therapy on mortality could be partly due to less adverse LV
remodeling, a pre-cursor of heart failure and our study
provides further support for the use ofMRA therapy in STEMI
patients. The mechanisms whereby MRA therapy contribute
to less adverse LV remodeling is likely due to blockade of
aldosterone-mediated increase in collagen synthesis23 and a
reduction in extracellular matrix turnover.24
On the other hand, in a randomized study of 100
patients with acute MI and LVEFb40%, Weir et al.25
previously showed that eplerenone provided minimal
incremental benefit against adverse LV remodeling over a
6 months period and these findings were attributed to the
use of optimal contemporary pharmacological therapies.
Of note, although they aimed to recruit patients with
LVEFb40%, the LVEF by CMRwas 51%when compared to
35% by screening echocardiography in the MRA group. It
may have been the relatively higher baseline LVEF in the
MRA therapy group in their study25 when compared to a
mean LVEF of 48% on the baseline scan in our group that
could have accounted for their findings.
The results from the pooled studies20 and meta-
analyses21,22 and our study support the need for an
adequately powered study and the CLEAR-SYNERGY
(NCT03048825) study (4000 patients; primary endpoint:
composite of cardiovascular death or new or worsening
heart failure at 2 years) has been designed to address this
and is currently recruiting patients.
Limitations
The inclusion criteria were strict but the study was
designed to identify those patients most likely to benefit
from cardioprotection (proximal occlusions with pre-PCI
TIMI 0 flow).5 995 patients were screened from 4 centers
over a 2-year period but only 67 patients had CMR data. CMR
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recruiting centers but transport was provided for patients to
go to another center (that was 1 and a half hours away) for
the scan.However, this resulted in a large number of patients
dropping out of the study following initial randomization.
Furthermore, following the publication of the ALBATROSS
trial19 and the study by van den Berg et al.,15 a decision was
made by the trial steering committee to stop the study early
due to slow recruitment and futility. Data on cardiac
enzymes were not reported due to small sample size and a
large number of missing data. However, MI size by CMR is
considered more robust26 and was available for themajority
of the patients in the study.
Conclusion
This pilot study showed no benefit of intravenous MRA
administered prior to reperfusion combined with 3 months
of oral MRA therapy on reducing MI size in STEMI patients
but there was an improvement in LV remodeling. Our pilot
data might help to design further studies that are adequately
powered to assess whether MRA therapy in STEMI patients
without heart failure could reduce reperfusion injury and
translate to an improvement in clinical outcomes.Acknowledgements
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